CO130 Subgroup Analysis of Quality-of-Life Outcomes in Patients Achieving F-VASI75: Pooled Results from Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.225
https://www.valueinhealthjournal.com/article/S1098-3015(22)00426-0/fulltext
Section Title :
Section Order :
10192
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00426-0&doi=10.1016/j.jval.2022.04.225